# Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

> **NCT00002994** · PHASE1 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 355 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** interleukin 2
- **BIOLOGICAL:** rhuMAb

## Key facts

- **NCT ID:** NCT00002994
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-07
- **Primary completion:** 2000-03
- **Final completion:** 2002-04
- **Target enrollment:** 355 (ACTUAL)
- **Last updated:** 2016-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002994, "Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00002994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*